Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Potential 450 day CR of first 25 patients

<< Previous

Bullboard Posts

Next >>

Comment by CancerSlayeron Apr 30, 2022 3:57pm

207 Views

Post# 34645126

RE:RE:Potential 450 day CR of first 25 patients

CancerSlayer wrote:

Eoganacht wrote: The 24% CR of the first 21 patients to reach 450 days = 5 out of 21 patients.

There are 4 more patients who need to be assessed at 450 days before the BTD application is submitted in 4Q2022.

If all 4 are found to be CR that's 9 out of the first 25 patients CR at 450 days (36%). So there is still the possibility of the first 25 attaining 36% CR at 450 days. And that includes the 12 undertreated patients.

Worst case scenario... even if all 4 are found to be NR, that's still a 20% CR (higher than Keytruda at 19%)...despite almost half of these patients being undertreated. Next worse case scenario... re: the remaining 4 unknowns, simply maintaining a 24% CR would only require 1 of the 4 to be CR, which is is a meaningful 26% increase in CR rate compared to Keytruda's 19%. All imo.

A bit off topic...but re: the NRs, it would be interesting to see down the line if systemically/IV administered TLD 1433 or Rutherrin would improve efficacy, especially considering the potential difficulties involved in the topical delivery of a suspended drug to a very irregular surface (bladder wall). Good luck...